Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-LEUKEMIA: Repurposing metformin as a leukemia-preventive drug in CCUS and LR-MDS
2024-518436-37-01Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of metformin in myelodysplastic syndrome (MDS) and clonal cytopenia of undetermined significance (CCUS) (2 arms), sponsored by Rigshospitalet. Primary endpoints: WP0 primary endpoint, WP1 primary endpoint - feasibility and 1 more. Planned start Jan 2025; status: authorised.
02
Drugs
metformin
03
Conditions
myelodysplastic syndrome (MDS)clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on 2024-518436-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518436-37-01.